Related Experiment Video
Updated: May 26, 2026
05:28
A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
Published on: May 15, 2019
Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated
Sook-Eun Park1, Marcus Lawson, Robert Dantzer
1Integrated Immunology and Behavior Program, University of Illinois at Urbana-Champaign, Illinois 61801-3873, USA.
Journal of Neuroinflammation
|December 23, 2011
Summary
Insulin-like growth factor (IGF)-I and its peptide GPE show antidepressant effects in rodent models. These compounds can prevent and treat depression-like behaviors induced by lipopolysaccharide (LPS), acting independently of sickness symptoms.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Centrally administered insulin-like growth factor (IGF)-I exhibits antidepressant activity in rodent models.
- Lipopolysaccharide (LPS) is known to induce depression-like behaviors in rodents.
Purpose of the Study:
- To investigate the preventive and curative effects of IGF-I and its derived peptide GPE on LPS-induced depression-like behavior.
- To determine if IGF-I and GPE affect LPS-induced sickness behaviors.
- To explore the impact of IGF-I and GPE on brain cytokine expression and tryptophan dioxygenases.
Main Methods:
- CD-1 mice were administered IGF-I or GPE centrally (intracerebroventricularly).
- LPS was administered intraperitoneally either 30 minutes after or 24 hours before IGF-I/GPE treatment.
- Depression-like behaviors were assessed using tail suspension and forced swim tests.
- Sickness behaviors (weight loss, food intake) and brain cytokine/enzyme expression were measured.
Main Results:
- IGF-I and GPE effectively abrogated LPS-induced depression-like behaviors, both preventively and curatively.
- Neither IGF-I nor GPE affected LPS-induced sickness behaviors such as weight loss or decreased food intake.
- GPE reduced brain cytokine expression in response to LPS, similar to IGF-I, but did not increase brain-derived neurotrophic factor (BDNF) expression.
Conclusions:
- IGF-I and GPE demonstrate specific antidepressant-like effects independent of sickness symptoms.
- The anti-inflammatory properties of IGF-I and GPE may underlie their antidepressant actions.
- GPE represents a potential therapeutic agent for depression, particularly when associated with inflammatory processes.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...